UNIVERSITY OF EDINBURGH

Saltwater nose drops reduced kids' cold duration by 2 days, per a study. Kids using the drops had symptoms for 6 days vs. 8 days with usual care. The drops also reduced medicine use and cold spread to family members. Parents found the drops effective and safe to administer at home.

Tiny magnetic nanobots, remotely guided as a swarm, could treat brain aneurysms by delivering blood-clotting drugs precisely, potentially revolutionizing minimally invasive medical treatments.

University of Edinburgh researchers developed tiny magnetic nanobots for treating brain aneurysms, potentially revolutionizing vascular treatments with less invasive, targeted drug delivery.

Cycling or walking to work significantly reduces risks of death, disease, and mental health issues, with cyclists seeing up to 47% lower risk of death. Active commuters are more likely to be young, shift workers, and city dwellers. The study highlights the need for safer cycling infrastructure and aligns with global efforts to promote active, sustainable travel.

Lecanemab, the first drug to slow Alzheimer's brain destruction, marks a historic breakthrough despite its modest effect and debate over real-world impact. Targeting amyloid, it offers hope for early-stage patients, yet challenges in early detection and treatment accessibility remain. Side effects and the need for further research highlight the complexity of Alzheimer's therapy.

Lecanemab, an experimental Alzheimer's drug, shows potential in slowing cognitive decline by 27% in Phase 3 trials, despite safety concerns. It reduces amyloid levels and cognitive decline more than placebo at 18 months but is associated with adverse events like brain swelling and bleeding. Longer trials are needed to confirm its efficacy and safety.

The Gordon Research Conference on Systems Aging 2022, chaired by Vadim Gladyshev and Steve Horvath, brought together leading scientists to discuss unpublished research on aging, rejuvenation, and longevity interventions. Highlights included talks on epigenetic reprogramming, aging clocks, and AI in aging research, with a focus on fostering collaboration and innovation in a confidential setting.

Newcastle University, University of Edinburgh, and Boehringer Ingelheim secured funding for a major liver cirrhosis study. University of New England received NIH support for the UNE Center for Cell Signaling Research. Oxitope Pharma and Arxx Therapeutics merged into Calluna Pharma Inc., focusing on antibodies for inflammatory and fibrotic conditions.